177 related articles for article (PubMed ID: 37598662)
21. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
[TBL] [Abstract][Full Text] [Related]
23. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
Newman KL; Johnson LA; Stidham RW; Higgins PDR
Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
[TBL] [Abstract][Full Text] [Related]
24. Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease.
Lightner AL; McKenna NP; Tse CS; Hyman N; Smith R; Ovsepyan G; Fleshner P; Crowell K; Koltun W; Ferrante M; D'Hoore A; Lauwers N; Verstockt B; Spinelli A; DiCandido F; Raffals LE; Mathis KL; Loftus EV
J Crohns Colitis; 2018 Mar; 12(4):402-407. PubMed ID: 29220430
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study.
Shim HH; Ma C; Kotze PG; Seow CH; Al-Farhan H; Al-Darmaki AK; Pang JXQ; Fedorak RN; Devlin SM; Dieleman LA; Kaplan GG; Novak KL; Kroeker KI; Halloran BP; Panaccione R
J Can Assoc Gastroenterol; 2018 Sep; 1(3):115-123. PubMed ID: 31294352
[TBL] [Abstract][Full Text] [Related]
26. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
Parrot L; Dong C; Carbonnel F; Meyer A
Aliment Pharmacol Ther; 2022 Feb; 55(4):380-388. PubMed ID: 34854100
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway.
Ihara Y; Torisu T; Miyawaki K; Umeno J; Kawasaki K; Hirano A; Fujioka S; Fuyuno Y; Matsuno Y; Sugio T; Sasaki K; Moriyama T; Akashi K; Kitazono T
Digestion; 2021; 102(6):946-955. PubMed ID: 34350861
[TBL] [Abstract][Full Text] [Related]
28. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
[TBL] [Abstract][Full Text] [Related]
29. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
30. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
Gisbert JP; Chaparro M
Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.
Kawalec P; Moćko P; Malinowska-Lipien I; Brzostek T
J Comp Eff Res; 2017 Oct; 6(7):601-612. PubMed ID: 28660802
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
[TBL] [Abstract][Full Text] [Related]
33. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
35. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
36. Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases.
Cheng D; Kochar BD; Cai T; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2366-2372.e6. PubMed ID: 35066137
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
[TBL] [Abstract][Full Text] [Related]
38. Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.
Liu R; Li Z; Ye L; Hu J; Tang J; Chen B; Chen X; Tan B; Gu Y; Xie C; Ouyang C; Song X; Li F; Fan Y; Ren H; Zhu L; Chen M; Jiang W; Cao Q
Inflamm Bowel Dis; 2024 Jan; 30(1):45-52. PubMed ID: 36880432
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies.
Tursi A; Mocci G; Del Gaudio A; Papa A
Expert Opin Biol Ther; 2024 Mar; 24(3):171-189. PubMed ID: 38321868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]